The multi-centre prospective study will evaluate the efficacy of the Rhenium-SCT® in non-melanoma skin cancer patients
Garching n. Munich, Germany–…
Australian Nuclear Science and Technology Organization (ANSTO), the new production partner of OncoBeta® GmbH in Australia
Innovative medical device Rhenium-SCT® therapy for non-melanoma skin cancer is now available in Australia
Province of Gauteng South Africa is first to offer an innovative single session keloid treatment without need of surgery
OncoBeta Announces Approval and ARTG Listing of Rhenium-SCT (Rhenium-188 paste) in Australia for the treatment of skin cancer lesions and skin tumors
Garching n. Munich, Germany, (December 18th, 2020) – OncoBeta® GmbH and their subsidiary OncoBeta Therapeutics Pty Ltd. Australia a Medical Device…
OncoBeta GmbH and Australian Nuclear Science and Technology Organisation sign Letter of Intent to establish manufacturing site in Australia
Innovative medical device Rhenium-SCT therapy for Non-Melanoma Skin Cancer to be produced in Australia
Group RPH and OncoBeta GmbH sign agreement for Sales Referral and Distribution of Rhenium-SCT® in Brazil.
Grupo RPH is now the Official Rhenium-SCT® Sales Representative and Distributor in Brazil for the treatment of Non-Melanoma Skin Cancer.
Personalized irradiation therapy for NMSC by rhenium-188 skin cancer therapy: a long-term retrospective study
Abstract Objectives This study aimed to provide long-term clinical data about an innovative epidermal radioisotope therapy called Rhenium-SCT® (Skin…
China Isotope & Radiation Corporation (CIRC) and OncoBeta sign distribution agreement for Tungsten 188/Rhenium-188 generators
Beijing, China and Garching near Munich, Germany, Tuesday 30th June 2020. CIRC and OncoBeta today announced that they have signed an agreement for the…